Thioridazine
Mellaril, Mellaril-s (thioridazine) is a small molecule pharmaceutical. Thioridazine was first approved as Mellaril-s on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 2C. In addition, it is known to target 5-hydroxytryptamine receptor 6, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, D(1B) dopamine receptor, histamine H1 receptor, G protein-activated inward rectifier potassium channel 2, and mucosa-associated lymphoid tissue lymphoma translocation protein 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| thioridazine hydrochloride | ANDA | 2021-12-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psychotic disorders | — | D011618 | F20.81 |
| schizophrenia | EFO_0000692 | D012559 | F20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | — | 1 | — | 1 | |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | 1 | — | 1 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | 1 | — | 1 | |
| Anesthesia | D000758 | — | — | — | 1 | — | 1 | ||
| Healthy volunteers/patients | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | F33.9 | — | — | 1 | — | 1 | 2 | |
| Septic shock | D012772 | A48.3 | — | — | 1 | — | — | 1 | |
| Traumatic brain injuries | D000070642 | S06 | — | — | 1 | — | — | 1 | |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esthetics | D004954 | — | 1 | — | — | — | 1 | ||
| Strabismus | D013285 | HP_0000486 | H50.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Memory disorders | D008569 | 1 | — | — | — | — | 1 | ||
| Amnesia | D000647 | EFO_1001454 | F44.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Phobic disorders | D010698 | EFO_1001908 | F40 | — | — | — | — | 1 | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | THIORIDAZINE |
| INN | thioridazine |
| Description | Thioridazine is a phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position. It has a role as a serotonergic antagonist, a H1-receptor antagonist, an alpha-adrenergic antagonist, a dopaminergic antagonist, a first generation antipsychotic, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and an EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor. It is a member of phenothiazines and a member of piperidines. It contains a methylsulfanyl group. |
| Classification | Small molecule |
| Drug class | Typical antipsychotic |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2 |
Target
Agency Approved
HTR2A
HTR2A
HTR2C
HTR2C
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HTR6
HTR6
DRD1
DRD1
HTR1A
HTR1A
HTR7
HTR7
DRD5
DRD5
HRH1
HRH1
KCNJ6
KCNJ6
MALT1
MALT1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,723 documents
View more details
Safety
Black-box Warning
Black-box warning for: Thioridazine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,197 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more